Menu ×

HEALTHCARE & PHARMACEUTICAL

Dengue Vaccine Market Segmentation By Age Group (<6 years, 6-12 years and >12 years) and By End User (Hospital, Clinics, Government Establishments, Private Establishments, Ambulatory Surgical Centers and Others) - Global Industry Demand Analysis and Opportunity Assessment 2018-2027

  • Text Size:

Extensive insights into the Growth of Dengue Vaccine Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More
IN THE NEWS
  • December 2018: One of the subsidiaries of Merck & Co., Inc. known as Merck Sharp & Dohme Corp. announced the collaboration with Instituto Butantan for the development of vaccines for dengue.

  • December 2018: Sanofi announced that the European Commission has granted marketing authorization for the dengue vaccine of Sanofi, known as Dengvaxia® in the European endemic areas.

Market Overview

The global dengue vaccine market is thriving on the back of growing concern for dengue diseases as well as the clinical advancements observed in the development of vaccines for dengue. A clinical process of any pharmaceutical product undergoes various phases. With the advancement in each phase, the effectiveness of the drug is also increased, which contributes to the greater adoption of the drug around the world. Moreover, advancements observed in the development of dengue vaccine for several age groups is also anticipated to raise the demand for greater adoption of the drug by nations worldwide, and in turn influence the growth of the global dengue vaccine market. The global dengue vaccine market is anticipated to cross a value of around USD 1100.0 million by the end of 2027 with a CAGR of around 22% during the forecast period 2019-2027.

Growth Highlights based on Region during 2018-2027

The global dengue vaccine market is segmented by regions into North America, Latin America, Europe, Asia Pacific and Middle East and Africa. Among these regions, the market of Asia Pacific dengue vaccine is driven majorly by China and India, where China is anticipated to hold the largest market share of around 30% share in the year 2027. Several outbreaks of dengue fever observed in the region over the years on the back of the region having a tropical environment, has raised the necessity of the government to increasingly focus on acquiring dengue vaccines in large quantity to address the massive population, which is majorly dominated by the two nations around the globe.

Further, Brazil, Mexico and Rest of Latin America are the prominent countries that are driving the growth of the Latin America dengue vaccine market. The Latin America region also has a tropical environment which is a favorable environment for the growth of the dengue disease. CLICK TO DOWNLOAD SAMPLE REPORT

Dengue Vaccine Market Share

 

The study further incorporates Y-O-Y Growth, demand & supply and forecast future opportunity in North America (United States, Canada), Latin America (Brazil, Mexico, Argentina, Rest of LATAM), Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Market Segmentation Synopsis

By Age Group

The global dengue vaccine market has been segmented on the basis of age group into <6 years, 6-12 years and >12 years. >12 years segment is anticipated to hold the largest market share of around 54% in the year 2027 in the global dengue vaccine market. Additionally, >12 years segment is anticipated to cross nearly USD 680 million by the end of 2027 by growing at a significant CAGR over the forecast period. Further, the <6 years segment is estimated to grow with the highest CAGR of around 22% over the forecast period.

Dengue Vaccine Market Share

By End User

The global dengue vaccine market is segmented by end user into hospital, clinics, government establishments, private establishments, ambulatory surgical centers and others. The clinics segment registered a significant market share along with a value of around USD 48 million in the year 2018. Clinics are the healthcare facilities which primarily focuses on the care of outpatients. Operated and managed both in private and in public sectors, clinics usually cover the primary healthcare needs of populations in the local communities. On the other hand, the hospital segment is anticipated to grow with a CAGR of around 22% during the forecast period. A hospital is a healthcare institution that provides treatment to patients with a specialized team or medical and nursing staffs. Hospitals are also equipped with medical equipment that are used to treat the patients.

Market Drivers and Challenges

Growth Indicators

According to the estimations of the World Health Organization (WHO), around 100-400 million dengue infections occur each year and that half of the world’s population is now at risk. Further, it also stated that over the last two decades, the number of dengue cases reported to the organization has increased over fifteen-fold, reaching up to 3,312,040 numbers in the year 2015.

The alarming increase in the number of dengue cases around the world is a major concern for individuals as well as the government of the nations. Moreover, due to the unavailability of the vaccine for the disease during its outbreak, several numbers of cases have been self-managed resulting in the actual number of dengue cases being under-reported. Apparently, several developed and under-developed nations around the globe are also prone to this disease on the back of unplanned and uncontrolled urbanization, poor management and others. The increasing concern for the spread of dengue virus around the world along with huge government funding for the manufacturing of the dengue vaccine, which led to greater affordability of the vaccine, are some of the factors anticipated to drive the growth of the global dengue vaccine market.

Barriers

Lack of awareness of the dengue vaccine as well as for the availability of the vaccine is anticipated to hamper the growth of the global dengue vaccine market.

Competitive Landscape

Some of the affluent industry leaders in the global dengue vaccine market are Merck & Co., Inc., Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited and Institut Pasteur. Moreover, numerous players are also increasingly investing on research and development activities for the launch of advanced form of dengue vaccines.

FREQUENTLY ASKED QUESTIONS

Global Dengue Market

Chapter 1 Preface

1.1 Report Description

1.1.1 Report Introduction

1.1.2 Target Audience

1.1.3 USP and Key Offerings

1.2 Research Scope

1.3 Market Segmentation

1.4 Research Methodology

1.4.1 Phase I – Secondary Research

1.4.2 Phase II – Primary Research

1.4.3 Phase III – Expert Panel Review

1.4.4 Assumptions

1.4.5 Approach Adopted

1.4.5.1 Bottom-Up Approach

1.4.5.2 Top down Approach

1.4.6 Data Triangulation

1.5 Research Assumptions

1.6 Data Sources

Chapter 2 Executive Summary

Chapter 3 Pipeline Analysis Of Dengue Vaccines

Chapter 4 Epidemiology Outlook Of Dengue Vaccines

4.1 Overview

 Chapter 5 Market Dynamics

5.1 Market Drivers

5.1.1 Rising Cases of Dengue

5.1.2 Affordability of Vaccine

5.2 Market Restraints

5.2.1 Lack of awareness

5.3 Opportunity

5.3.1 Clinical Development of Vaccines

Chapter 6 Global Dengue Vaccine Market Analysis, by Demography

6.1 Overview

6.2 Below 5 years

6.3 5-10 years

6.4 Above 10 years

Chapter 7 Global Dengue Vaccine Market Analysis, By End- User

7.1 Overview

7.2 Clinics

7.3 Hospital

7.4 Ambulatory Surgical Centers

7.5 Government/Private Institutes

7.6 Others

Chapter 8 Global Dengue Vaccine Market Analysis

8.1 Introduction

Chapter 9 North America Dengue Vaccine Market Analysis

9.1 Overview

Chapter 10 Europe Dengue Vaccine Market Analysis

10.1 Overview

Chapter 11 Asia Pacific Dengue Vaccine Market Analysis

11.1 Overview

Chapter 12 Latin America Dengue Vaccine Market Analysis

12.1 Overview

12.1.1 Latin America

Chapter 13 Middle East & Africa Dengue Vaccine Market Analysis

13.1 Overview

Chapter 14 Company Profiles

14.1 Sanofi

14.2 Merck & Co., Inc.

14.3 Institut Pasteur

14.4 Takeda Pharmaceutical Company Limited

14.5 GlaxoSmithKline Plc

Chapter 15 Global Strategy of The Companies

15.1 Overview

15.2 Dengue vaccine candidates currently in clinical trials


Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved